Reviewer's report

Title: Inter-jurisdictional cooperation on pharmaceutical product listing agreements: lessons from Canada

Version: 1 Date: 20 November 2012

Reviewer: Mondher Toumi

Reviewer's report:

Description of methods and results
- Give the description of the profiles of responders with keeping them anonymous.
- On which criteria were selected the responders? Are they homogeneous? What precisely are their role?
- Which other responders could have been interviewed and what is the limit of the choice done?
- Why the one who refused to participate has not been replaced by another person?
- If the size of the region got an impact on the choices, the results may be presented by region or at least by cluster of 3 regions (small, medium, big).
- The different policies, the policies concomitants, the political healthcare priorities should be more explicated.

Limitations
- The experience of the interviewee is not assessed. The perspective is restricted to that of how authorities could take advantage of an inter-jurisdiction cooperation. It does not explain the way it could be implemented though a full loss of power from the province toward that decision making body which none of the provinces are likely to accept. This should be better elaborate.

In the discussion, it should be wise to discuss experience of their highly decentralise countries such as Italy or Spain and even Germany where many PLA are performed at the launder level.

Interesting and important paper deserve to be published after important revision. At that stage the methods and results are too vague. It looks rather as a pilot project before a more deep survey.